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Abstract
Background: Under the National Childhood Immunisation Schedule (NCIS) in Singapore most vaccines are
provided free while some, including pneumococcal conjugate vaccines (PCV), added to the NCIS in October 2009,
are not free. In contrast to ≥95 % coverage achieved for recommended childhood vaccines that are free, 2013
coverage of the PCV booster dose was 58.9 % (for unclear reasons). To date, no population impact on
pneumococcal disease (PD) has been observed. We conducted a questionnaire-based study of parents of young
children to assess the value of PCV to parents, and to quantify the extent to which vaccine cost is a barrier to PCV
uptake in Singapore.
Methods: A single, trained interviewer administered a questionnaire to 200 parents ≥21 years of age with young
children attending the Singapore Sengkang Polyclinic. The questionnaire asked closed-ended questions on parents’
knowledge about PD and PCV. A 5-point Likert scale measured perceived benefits and barriers to PCV vaccination.
Results: There were 162 parents whose children were either PCV-vaccinated or who intended to vaccinate their
child with PCV (Vaccinated group), and 38 whose children were non-PCV vaccinated or who did not intend to
vaccinate (Unvaccinated group). The odds ratio for PCV vaccination among parents who perceived cost as a barrier
was 0.16 (95%CI 0.02–1.23). Compared to the Vaccinated group, parents in the Unvaccinated group were less
willing to pay for PCV (50.0 %/94.4 %). Compared to the Vaccinated group, fewer parents in the Unvaccinated
group had heard about PD (34.2 %/82.1 %) or PCV (36.8 %/69.1 %), or perceived that PD was a threat to their child.
Fewer parents in the Unvaccinated group knew that vaccination could prevent PD (28.9 %/77.8 %), or reported that
PCV vaccination was recommended to them by any source (63.2 % had no PCV recommendation, versus 20.4 %).
When informed that PCV is included in the NCIS only 65.8 % of parents in the Unvaccinated group, versus 98.8 % in
the Vaccinated group, indicated that they would be willing to vaccinate their child.
Conclusions: Cost considerations, not having vaccination recommended to parents and a lack of knowledge
among parents of the benefits of PCV to the child may adversely impact PCV uptake in Singapore.
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Background
Streptococcus pneumoniae is one of the major causes of
bacterial meningitis, sepsis and respiratory infection in
children [1]. The World Health Organization (WHO) es-
timates that 476,000 deaths in children <5 years of age
in 2008 were caused by pneumococcal infection [2].
Currently licensed pneumococcal conjugate vaccines
(PCVs) have proven to be highly effective in preventing
morbidity and mortality due to Invasive Pneumococcal
Disease (IPD), pneumonia and otitis media in children,
with evidence of herd protection in unvaccinated age
groups [3, 4].
Prior to the availability of PCVs in Singapore (2005),
the annual incidence of hospitalised “pneumococcal
disease” (defined using the International Classification of
Disease ICD-9 codes that included pneumococcal
pneumonia, meningitis, peritonitis, septicaemia and a
less specific code for pneumococcal bacterial infection in
unspecified sites) among children <5 years of age was es-
timated to be 38.4/100,000 population (1997–2004) [5].
The annual incidence in Singapore was similar to the
overall incidence of IPD in Europe prior to PCV imple-
mentation (31.1/100,000: estimated from multiple stud-
ies of diverse design among cohorts aged ≤6 years
between 1980 and 2005) [6]. By contrast, using a more
stringent case definition of positive cultures collected
from children aged <5 years admitted to the KK
Women’s and Children’s Hospital, the largest children’s
hospital in Singapore, (1998–2004), the annual incidence
of laboratory-confirmed IPD was 13.3/100,000 popula-
tion [7]. The annual incidence in children aged <2 years
was 16.9/100,000 population [7]. In another study the
annual incidence of IPD requiring hospitalisation among
<5 year olds in Hong Kong was 15.6/100,000 from 1995
to 2004 and 16.1/100,000 from 2000 to 2005) [8].
Compliance with the National Childhood Immunisation
Schedule in Singapore is generally very high, with at least
95 % coverage of recommended vaccines that are provided
free to families; for example, 2012 coverage of the third
dose of hepatitis B and poliovirus vaccines was 97 % [9].
The 7-valent PCV (PCV7) was licensed in Singapore in
2005 and was recommended in the National Childhood
Immunisation Schedule from October 2009, but at a cost
to families [10]. PCV in Singapore is administered as a 2-
dose primary immunisation course at 3 and 5 months of
age, with a booster administered at 12 months of age. In
2013 coverage of two doses of PCV in Singapore by age
1 year was 79.6 %, and coverage of the booster dose by age
2 years was 58.9 % [11]. PCV vaccination has been associ-
ated with a decrease in paediatric IPD due to vaccine-
serotypes in Singapore (PCV7 and PCV13 after 2011), and
a commensurate increase in IPD due to non-vaccine
types, with no change in overall IPD notifications in chil-
dren since the introduction of PCV [12–14].
Thus, although PCV has been included in the NCIS in
Singapore for six years, coverage remains low, and a
population impact on IPD has not been observed [12].
Assuming the total cost of the recommended 3-dose
schedule in Singapore is $500, the cost of one dose is ap-
proximately $167 [15]. The average household monthly
income per household member in 2014 was $2380 [16].
Therefore, the cost of one dose represents 7 % of the
average household monthly income per household mem-
ber. Singapore’s gross domestic product per capita is one
of the highest in the world [17]. In a survey of mothers
of young children in Japan, another high income coun-
try, low coverage of voluntary vaccines (rotavirus,
mumps, varicella and hepatitis B) was primarily attrib-
uted to vaccine cost [18]. In a study conducted in
Indonesia, a low-middle income country, vaccine cost
and lack of knowledge about the severity of the targeted
disease were important factors that influenced PCV up-
take [19].
We conducted a questionnaire-based study of parents,
the primary decision makers and payers of elective vac-
cinations on the national schedule, of young children in
order to assess the value of PCV to parents, and to
quantify the extent to which the cost of the vaccine is a
barrier to the uptake of PCV in Singapore. We also ex-




This was an observational, cross-sectional interviewer-
administered survey conducted at the SingHealth Poly-
clinic in Sengkang, Singapore between 14 May 2014 and
09 July 2014. SingHealth is one of two public health pro-
viders and provides primary care (including immunisa-
tion) in the central east and north-east regions of
Singapore. SingHealth encompasses a network of nine
polyclinics; the Sengkang polyclinic was selected as the
study site because it serves the fastest growing new resi-
dential estate in Singapore, with a dense concentration
of young families [20]. The distribution of young
children resident across Singapore is heterogeneous [21].
Together, Sengkang and the adjacent region of Punggol
form the most concentrated population of children less
than 5 years of age in Singapore [21]. Conducting the
study in the most concentrated population of subjects of
interest is likely to be representative of parents and
children across Singapore.
Eligible parents were ≥21 years of age, had at least one
child born on or after 01 November 2009, and had
brought their child to the vaccination clinic at the
SingHealth Polyclinic in Sengkang. Individuals could
only complete the survey once.
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The study was approved on 07 February 2014 by
the SingHealth Centralised Institutional Review Board
(Ref: 2014/116/E) and conducted in accordance with
the Declaration of Helsinki and ‘good clinical practice’
principles. All participants gave written informed
consent before enrolment. All data collected were
anonymous.
Survey methods and data collection
The study questionnaire assessed the knowledge and at-
titudes of parents across three broad domains: know-
ledge about pneumococcal disease, knowledge about
PCV, and the perceived benefits and barriers of vaccin-
ation with PCV. The questionnaire was pilot-tested in
10 volunteers prior to study start to assess comprehen-
sion and to determine the time needed to conduct the
interviews. The questionnaire was translated into the
major languages of Singapore by a professional transla-
tor. The translations were submitted to the SingHealth
Centralised Institutional Review Board.
All questionnaires were administered by a single,
trained, interviewer who was not a member of the Poly-
clinic staff and not involved in administering childhood
vaccinations. After explaining the study and enrolling
the subject, the interviewer recorded basic demographic
information and socioeconomic status. The interviewer
asked participants for their responses to a series of
closed-ended questions under the ‘knowledge about
pneumococcal disease’ and ‘knowledge about PCV’ do-
mains. Parent’s knowledge about the risk, cause, severity
and clinical manifestations of pneumococcal disease and
how it can be prevented was assessed. Parents were
questioned about PCV, including its availability on the
National Childhood Immunisation Schedule and infor-
mation sources and factors influencing their decision to
vaccinate. Benefits, such as the ability of the vaccine to
protect, and barriers to vaccination including the per-
ception of harms, costs, and issues of vaccine access,
were recorded on a 5-point Likert scale. Each interview
lasted approximately 20–30 min. The full list of
questions and responses is provided in the Supplement
(Additional file 1: Table S1, Additional file 2: Table S2,
Additional file 3: Table S3, Additional file 4: Table S4).
Subjects were approached using a systematic sampling
frame. Appointment numbers for pre-booked and ‘walk-
in’ patients were randomly mixed according to time of
arrival to the clinic, or time of transfer from other clinic
service stations to the vaccination queue list. A sampling
frame of one in five numbers was applied to the queue
display pad in the vaccination service room; that is, the
first, sixth, 11th and so on. The queue numbers in those
positions were called out in the waiting area and the
parents holding these identified queue numbers were
then invited for screening for eligibility.
Statistical analysis
There were two study groups: those parents whose
children were either PCV-vaccinated or who intended to
vaccinate their child with PCV (Vaccinated group), and
those parents whose children were not vaccinated with
PCV, or who did not intend to vaccinate their child with
PCV (Unvaccinated group).
We used a logistic regression model to quantify the
extent to which vaccine cost and the other survey do-
mains influenced uptake. Odds ratios (OR) with 95 %
confidence intervals (CI) were calculated for PCV
vaccination (dependent variable) based on whether cost
(independent variable) was indicated as being too high.
Ordinal outcomes (5-point Likert scale information re-
lated to the question ‘the cost of the PCV is too high’)
were converted into a binary response, with values below
the “neutral” response considered as “No” and values
above the “neutral” response considered as “Yes” for bar-
riers in terms of cost. Those subjects who answered
“neutral” to the independent variable were not included
in the logistic regression analysis related to the primary
endpoint.
Sensitivity analyses using the 5-point Likert scale in-
formation as continuous independent variables (consid-
ering the score of 1 to 5) were also conducted using a
logistic regression model.
Descriptive summary statistics (frequencies and per-
centages) for all domains, as well as the polychoric cor-
relation co-efficient between the 15 items measured on
the 5-point Likert scale related to the perceived benefits
and barriers to vaccination domain, was computed. Ex-
ploratory post-hoc analyses compared groups in terms
of their demographic characteristics, parental attitudes
and intentions concerning PCV based on cost factors,
and parent’s knowledge about pneumococcal disease and
PCV, using the Fisher’s exact test or Mann-Whitney-
Wilcoxon test.
In view of the sample size, the number of items related
to perceived benefits and barriers to vaccination and the
expected correlation among these items, an exploratory
factor analysis using polychoric correlation co-efficient
was performed. The factor analysis reduced the large
number of variables of interest to a smaller group of
unobservable (latent) factors. This was followed by a
multiple logistic regression model that considered vac-
cination status as the dependent variable and the identi-
fied latent factors as independent variables [22]. A
p-value <0.05 was used to indicate that a statistically sig-
nificant difference might exist between groups.
Sample size
The sample size was estimated based on the assumed
theoretical proportions of affirmative responses in terms
of cost being a barrier to the uptake of PCV. We
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assumed that PCV vaccine coverage in Singapore might
be around 50 % at the time of the study, and that cost
might be a barrier to vaccination in 25 % of families.
Considering an even distribution of responses across the
5-point Likert scale to the question’the cost of PCV is too
high’, and that 20 % of parents would respond ‘Neutral’
to this statement, the study had 81 % power to detect an
OR of four in the proportion of affirmative responses be-
tween Vaccinated and Unvaccinated groups (or an OR
of 0.25 in the Unvaccinated compared to the Vaccinated
group), when there were 80 subjects in each group
(Total enrolled cohort of 200).
The statistical analyses were performed using SAS®
version 9.2 and SAS® Drug and Development version
3.5. We used PASS version 2005 software for sample size
calculations.
Results
Characteristics of the study population
There were 200 parents enrolled and all contributed data
to the final analysis. There were 162 parents in the Vac-
cinated group and 38 parents in the Unvaccinated group.
The median age of the child at interview was 6 months
(range 0–27 months) in the Vaccinated group and
4 months (range 0–19 months) in the Unvaccinated
group. The interviewees were mothers for 68.5 and 57.9 %
of children in the respected groups. Demographic features
of the Vaccinated and Unvaccinated parents appeared to
be similar (Table 1) (p > 0.05 for all characteristics).
Children in the Unvaccinated group appeared to be youn-
ger than children in the Vaccinated group (p < 0.01).
Cost as a barrier to PCV vaccination
There were 63.0 % (126/200) of parents overall
(61.1 % [99/162] of parents in the Vaccinated group
and 71.1 % [27/38] in the Unvaccinated group) who
answered ‘Moderately Agree’ or ‘Strongly Agree’ to
the question ‘The cost of PCV is too high’ (Table 2).
The OR for PCV vaccination with cost as a barrier
was 0.16 (95 % CI 0.02–1.23): that is, the odds (or
likelihood) of letting their child be vaccinated with
PCV was 0.16 in the group of parents who believed
that cost is a barrier, when compared to the parents
who did not believe that cost is a barrier.
Table 1 Demographic characteristics of interviewed parents according to PCV vaccination status of their child
Characteristics Categories Vaccinated group Unvaccinated group
N = 162 N = 38
Age of the child at interview in months Mean (SD) 7.3 (5.6) 4.8 (5.1)
Median (range) 6 (0–27) 4 (0–19)
Age category of the interviewed parent, n (%) 21–30 years 59 (36.4) 15 (39.5)
31–40 years 97 (59.9) 18 (47.4)
≥41 years 6 (3.7) 5 (13.2)
Gender of the interviewed parent, n (%) Male 51 (31.5) 16 (42.1)
Female 111 (68.5) 22 (57.9)
Ethnicity, n (%) Chinese 86 (53.1) 19 (50.0)
Indian 8 (4.9) 3 (7.9)
Malay 62 (38.3) 15 (39.5)
Other 6 (3.7) 1 (2.6)
Residency status, n (%) Permanent Resident 10 (6.2) 2 (5.3)
Singapore citizen 149 (92.0) 36 (94.7)
Other 3 (1.9) 0 (−)
Highest education of the interviewed parent, n (%) Primary 2 (1.2) 2 (5.3)
Secondary 30 (18.5) 8 (21.1)
Post-secondary 130 (80.2) 28 (73.7)
Combined monthly household income, n (%) <1000 SGD 4 (2.5) 1 (2.6)
1001 to 3000 SGD 36 (22.2) 12 (31.6)
3001 to 5000 SGD 54 (33.3) 11 (28.9)
>5000 SGD 58 (35.8) 11 (28.9)
Prefer not to answer 10 (6.2) 3 (7.9)
Vaccinated group Parents whose children had received PCV or parents who intended to have their child vaccinated, Unvaccinated group Parents whose children
had not received PCV or parents who had no intention of having their child vaccinated, N total number of parents, n (%) number (percentage) of parents in a
given category, PCV pneumococcal conjugate vaccine, SD standard deviation, SGD Singapore dollars
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In sensitivity analysis after the 5-point Likert scale was
treated as a continuous variable, (using the scores from
1 to 5 for strongly disagree to strongly agree), cost
remained a barrier (OR 0.73).
Compared to parents in the Vaccinated group, par-
ents in the Unvaccinated group were less willing to
pay for PCV vaccination (94.4 % Vaccinated, 50.0 %
Unvaccinated) (Table 2). For those that were willing
to pay, 16.3 % in the Vaccinated group were willing
to pay 101 to 150 SGD (Singapore Dollar) per dose,
versus 0 % in the Unvaccinated group (Table 2).
Parents in the Unvaccinated group were also less will-
ing to vaccinate with PCV if the vaccine was free
(76.3 % Unvaccinated, 99.4 % Vaccinated), suggesting
that cost was not the only factor affecting uptake. Of
the 9 parents who were unwilling to vaccinate if PCV
was free, 3 did not know about pneumococcal disease
and one was not aware of PCV.
Knowledge and attitudes as barrier to PCV vaccination
Compared to the Vaccinated group, fewer parents in the
Unvaccinated group had heard about pneumococcal dis-
ease (82.1 % Vaccinated, 34.2 % Unvaccinated) or PCV
(69.1 % Vaccinated, 36.8 % Unvaccinated) (Table 3).
There were fewer parents in the Unvaccinated group
than the Vaccinated group who knew that babies were at
risk of pneumococcal disease (61.5 % Unvaccinated,
81.2 % Vaccinated), or who perceived that pneumococcal
disease was a threat to their child. Fewer parents in the
Unvaccinated group knew that vaccination could pre-
vent pneumococcal disease (84.6 % Unvaccinated, 94.7 %
Vaccinated), or had PCV vaccination recommended to
them by any source (63.2 % in the Unvaccinated group
had no PCV recommendation versus 20.4 % in the Vac-
cinated group). Information from healthcare profes-
sionals was the most influential source of information
for both groups. Twice the proportion of parents in the
Unvaccinated group versus the Vaccinated group indi-
cated that the internet was the most influential source of
information (34.2 % Unvaccinated, 13.6 % Vaccinated).
Knowing that PCV is included in the National
Childhood Immunisation Schedule in Singapore, only
65.8 % of parents in the Unvaccinated group, versus
98.8 % in the Vaccinated group, indicated that they
would be willing for their child to be vaccinated.
Perceived benefits and barriers to PCV vaccination
Of 15 questions in the ‘Perceived benefits and barriers to
PCV vaccination’ domain, 13 items correlated with at
least one other item with a polychoric coefficient value
of ≥0.30 (Additional file 5: Table S5), suggesting reason-
able factorability; that is, items have a weak to strong
positive relationship.
Table 2 Parental attitudes and intentions concerning PCV based on cost factorsa







The cost of PCV is too high (5-Point Likert scale)b Strongly Disagree 7 (4.3) 0 (−) 0.21
Moderately Disagree 16 (9.9) 1 (2.6)
Neutral 40 (24.7) 10 (26.3)
Moderately Agree 49 (30.2) 12 (31.6)
Strongly Agree 50 (30.9) 15 (39.5)
If the PCV was free of charge, would you be
willing for your child to be vaccinated with
the vaccine?
No 1 (0.6) 9 (23.7) <0.01
Yes 161 (99.4) 29 (76.3)
If you had to pay for the PCV, would you be
willing for your child to be vaccinated with
the vaccine?
No 9 (5.6) 19 (50.0) <0.01
Yes 153 (94.4) 19 (50.0)
How much are you willing to pay for your
child to be vaccinated with the PCV?
<50 SGD per jab 73 (47.7) 13 (68.4)
50 to 100 SGD per jab 55 (35.9) 6 (31.6) 0.14
101 to 150 SGD per jab 25 (16.3) 0 (−)
Do you intend to let your child receive the PCV? Yes 76 (46.9) 0 (−) -
No 0 (−) 38 (100)
Already vaccinated 86 (53.1) 0 (−)
Vaccinated group Parents whose children had received PCV or parents who intended to have their child vaccinated, Unvaccinated group Parents whose children
had not received PCV or parents who had no intention of having their child vaccinated, N total number of parents, n (%) number (percentage) of parents in a
given category, PCV pneumococcal conjugate vaccine, SGD Singapore dollars
p-values using Fisher's exact test
aSubset of questions and responses. Responses to all questions are provided in full in the Supplement
bThe odds ratio for PCV vaccination among parents who perceived cost as a barrier was 0.16 (95 % CI 0.02–1.23)
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Table 3 Parental knowledge concerning pneumococcal disease and PCVa
Vaccinated group N = 162
n (%)
Unvaccinated group N = 38
n (%)
p-value
Have you heard about
pneumococcal disease?
Yes 133 (82.1) 13 (34.2) <0.01
No 29 (17.9) 25 (65.8)
Are babies at risk of
developing pneumococcal
disease?b
Yes 108 (81.2) 8 (61.5) 0.13
No 7 (5.3) 1 (7.7)
Do not know 18 (13.5) 4 (30.8)
Can vaccination prevent
pneumococcal disease?b
Yes 126 (94.7) 11 (84.6) 0.18
No 7 (5.3) 2 (15.4)
Do not know 29 (21.8) 2 (15.4)
The chance of your child
catching pneumococcal
disease is;b
Very likely 7 (5.3) 0 (−) 0.19
Moderately likely 36 (27.1) 1 (7.7)
Neither likely nor unlikely 58 (43.6) 9 (69.2)
Moderately unlikely 24 (18.0) 2 (15.4)
Very unlikely 8 (6.0) 1 (7.7)
The consequences of
pneumococcal disease
for a child are;b
Very severe 68 (51.1) 4 (30.8) 0.08
Moderately severe 41 (30.8) 4 (30.8)
Neither severe or mild 21 (15.8) 3 (23.1)
Moderately mild 0 (−) 1 (7.7)
Very mild 3 (2.3) 1 (7.7)
Have you heard about
PCV before?
Yes 112 (69.1) 14 (36.8) <0.01
No 50 (30.9) 24 (63.2)
Is PCV included in the
NIP in Singapore?
Yes 92 (56.8) 13 (34.2) 0.01
No 29 (17.9) 6 (15.8)
Do not know 41 (25.3) 19 (50.0)
PCV does more good
than harm
Strongly Disagree 1 (0.6) 0 (−) <0.01
Moderately Disagree 1 (0.6) 1 (2.6)
Neutral 25 (15.4) 21 (55.3)
Moderately Agree 68 (42.0) 14 (36.8)
Strongly Agree 67 (41.4) 2 (5.3)
The PCV vaccine works Neutral 95 (58.6) 32 (84.2) <0.01
Moderately Agree 45 (27.8) 6 (15.8)
Strongly Agree 22 (13.6) 0 (−)
There are too many doses
required for vaccination
with the PCV
Strongly Disagree 6 (3.7) 1 (2.6) 0.95
Moderately Disagree 11 (6.8) 2 (5.3)
Neutral 54 (33.3) 11 (28.9)
Moderately Agree 63 (38.9) 18 (47.4)
Strongly Agree 28 (17.3) 6 (15.8)
My child does not need
the PCV as he/she is strong
enough to cope with
pneumococcal disease
Strongly Disagree 49 (30.2) 1 (2.6) <0.01
Moderately Disagree 67 (41.4) 7 (18.4)
Neutral 43 (26.5) 26 (68.4)
Moderately Agree 2 (1.2) 4 (10.5)
Strongly Agree 1 (0.6) 0 (−)
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In the factors analysis, communalities for 10 out of 15
items were >0.25, confirming that each item shared
some common variance with other items (Table 4). The
higher the factor loading (or score), the greater the likely
influence of the item on the particular factor. For ex-
ample, Factor 1 has characteristics very similar to items
1, 8, 9 and 12. The questions related to these items indi-
cate that Factor 1 relates to “perceived benefits” and that
similarly, Factor 2 relates to “perceived barriers”. The
two-factor solution was preferred as it explained 82.7 %
of the overall variance.
The OR for Factor 1 from the logistic regression
model suggests that the likelihood of parents letting
their child vaccinated increases by 5.2 times with each
one unit increase in the standardised items related to
“perceived benefits” (p-value <0.01) (Table 5). Factor 2
suggests the likelihood of parents letting their child vac-
cinated decreases by 0.75-fold with each one unit in-
crease in the standardized items which are believed to
be “barriers” (not statistically significant).
Discussion
Parents make the decision as to whether or not their
child receives vaccines. The knowledge, perceived
benefits and factors that influence the decision to vac-
cinate are complex. The decision not to vaccinate has
direct implications for the health and well-being of indi-
vidual children and for the wider community should
herd protection effects fail to be achieved due to low
coverage in the paediatric population. The uptake of
vaccines in the NCIS that are provided free in Singapore
is very high [11], which is in marked contrast to that of
PCV, which comes at a cost to families, suggesting that
cost may be a barrier to vaccination with PCV. We used
a questionnaire to explore the perceived benefits and
barriers to PCV vaccination in Singapore in order to es-
timate the value of PCV to parents.
More parents in the Unvaccinated group had not heard
about pneumococcal disease or PCV vaccination, and these
parents perceived less threat from pneumococcal disease
and less benefit from PCV vaccination than parents in the
Vaccinated group. Furthermore, more parents in the Un-
vaccinated group had not had PCV recommended to them
by a healthcare professional. These results suggest that ef-
forts and activities to improve parental knowledge about
IPD could impact positively on the perceived value of PCV
vaccination, which can influence parents’ decisions to
vaccinate. An increased role of healthcare providers could
Table 3 Parental knowledge concerning pneumococcal disease and PCVa (Continued)
There are too many
childhood vaccinations
for my child to take
Strongly Disagree 9 (5.6) 2 (5.3) 0.05
Moderately Disagree 20 (12.3) 0 (−)
Neutral 39 (24.1) 7 (18.4)
Moderately Agree 63 (38.9) 15 (39.5)
Strongly Agree 31 (19.1) 14 (36.8)
Who recommended that
your child receive the PCVc
Doctor 51 (31.5) 6 (15.8) –
Nurse 88 (54.3) 9 (23.7)
Friends or Family 20 (12.3) 2 (5.3)
Child care/day care 2 (1.2) 0 (−)
No one recommended 33 (20.4) 24 (63.2)
Which of the following
sources of information
would you consider most
influential to your decision
making regarding vaccination
with PCVc?
Healthcare Professional 151 (93.2) 33 (86.8) –
Media: TV, radio, newspapers, magazines 40 (24.7) 9 (23.7)
Friend, family members 51 (31.5) 13 (34.2)
Brochures, leaflets, posters in doctor clinics 78 (48.1) 19 (50.0)
The internet 22 (13.6) 13 (34.2)
Other 3 (1.9) 0 (-)
Knowing the PCV is included
in the NIP in Singapore. Would
you be willing for your child
to be vaccinated with the PCV?
Yes 160 (98.8) 25 (65.8) <0.01
No 2 (1.2) 13 (34.2)
Vaccinated group Parents whose children had received PCV or parents who intended to have their child vaccinated, Unvaccinated group Parents whose children
had not received PCV or parents who had no intention of having their child vaccinated, N total number of parents, n (%) number (percentage) of parents in a
given category, PCV pneumococcal conjugate vaccine, SGD Singapore dollars, NIP National Childhood Immunisation Programme
p-values using Fisher’s exact test
aSubset of questions and responses. Responses to all questions are provided in full in the Supplement
bDenominator does not include parents who stated that they did not know about pneumococcal disease
cSince a subject can choose more than one option, the percentages will not add up to 100 %
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potentially impact vaccine uptake, through communicating
the risks of IPD and benefits of vaccination to parents dir-
ectly, and indirectly through provision of informative mate-
rials, and via the internet.
Under the ‘perceived benefits and barriers to PCV vac-
cination’ domain, barriers to vaccination appeared to be
the cost of PCV, concerns about PCV side-effects, a per-
ception that there are too many childhood vaccines and
too many PCV doses, and issues linked to vaccine ac-
cess; either because of lack of parental time, or costs as-
sociated with transport to the clinic. The administration
of combination vaccines has been linked to improved ac-
ceptability and coverage rates [23, 24]. Identification of
ways to reduce the number of injections required to
complete the Singapore vaccination schedule could also
improve coverage of PCV, with benefits that could ex-
tend to other new vaccines potentially being considered
for introduction into the schedule.
This is the first study conducted at a local level to ex-
plore the reasons why parents in this community in
Singapore do not vaccinate their children with PCV.
The study was conducted at a time when the importance
Table 4 Communality estimates and variance of the items from perceived benefits and barriers domain – Factor analysisa
Factor loadingsb
Item (Perceived benefits and barriers) Factor 1 Factor 2 Communality estimates
1 By allowing my child to take the PCV I will help
protect my child from pneumococcal disease
0.82 – 0.68
2 There are too many doses required for
vaccination with the PCV
– 0.70 0.50
3 The number of doses of PCV will influence
my decision whether to vaccinate my child
at a younger or older age
– 0.52 0.27
4 My child does not need the PCV as he/she
is strong enough to cope with pneumococcal
disease
–0.65 – 0.44
5 PCV causes disease –0.31 0.38 0.24
6 Vaccination with PCV is too painful for my
child
–0.25 0.45 0.27
7 There are too many childhood vaccinations
for my child to take
– 0.68 0.50
8 PCV does more good than harm 0.84 – 0.72
9 It is my responsibility to ensure that my child
is vaccinated against pneumococcal disease
0.80 – 0.64
10 It is not easy for me to find time to bring my
child to the clinic for the PCV
– 0.37 0.14
11 Transportation to the clinic for PCV is a
problem
– 0.27 0.10
12 The PCV works 0.53 – 0.28
13 There is no long term benefit of the PCV −0.24 0.26 0.13
14 There are short-term side effects from the PCV – 0.32 0.10
15 The cost of the PCV is too high – 0.52 0.27
Percentage explained (%) – – 82.70
Communality: Proportion of variance in items explained by the factors
Percentage explained: Proportion (Percentage) of variance in the data that is explained by all the factors
PCV pneumococcal conjugate vaccine
aFactor Analysis (using PROMAX rotation; Unweighted Least Squares [ULS] method; Squared Multiple Correlations [SMC] Priors and MINIMUM EIGEN value >1 to
retain the number of factors) was performed to identify the latent factors for perceived benefits and barriers
bFactor loadings < 0.2 are suppressed
Table 5 Estimated coefficients of the fitted logistic regression model for PCV uptake with influencing benefits and barriers as factors
Parameters or Categories Coefficient Standard error P-value Adjusted ORa (95 % CI)
FACTOR 1 (Perceived benefits) 1.69 0.30 <0.001 5.24 (2.89; 9.52)
FACTOR 2 (Perceived barriers) −0.50 0.31 0.36 0.75 (0.40; 1.39)
OR odds ratio, PCV pneumococcal conjugate vaccine, 95 % CI of OR 95 % confidence interval of Odds ratio
athe OR for Factor 1 was adjusted for Factor 2, and the OR for Factor 2 was adjusted for Factor 1
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of PCV has been recognised by inclusion into the NCIS
by policy-makers, but when the benefits of vaccination at
a population level have not been optimal. The study ques-
tionnaire was refined during a pilot phase and we believe
that this improved its internal validity and utility. The ex-
ploratory factor analysis and logistic regression indicated
that an increase in the perceived benefits of vaccination
(i.e., value proposition) is likely to have a greater influence
on the decision to vaccinate than attempting to change
perceived barriers. The identification of actionable factors
provides evidence about which public health measures,
health promotion or policy changes could positively influ-
ence the perceived value of vaccination.
Our study is potentially limited because the observed
percentage of parents who reported ‘neutral’ to the ques-
tion ‘the cost of PCV is too high’, and thus eliminated
from the analysis of the primary endpoint, was some-
what higher than anticipated (25 % versus 20 %). Add-
itionally, the distribution of parents between Vaccinated
and Unvaccinated groups was not equal (81 % in Vacci-
nated group and 19 % in the Unvaccinated group),
whereas the study was powered according to a 50:50 dis-
tribution. Therefore, while the study identified cost as a
likely factor influencing parents uptake of PCV, the asso-
ciation was not statistically significant and a definitive
conclusion about cost as a barrier cannot be drawn.
Finally, our survey was limited to one of the 18 public
health centres serving the whole of Singapore, and the
conclusions may not be applicable to private clinics.
Conclusion
Infant vaccination with PCV has been included in the
NCIS in Singapore since 2009 but coverage remains sub-
optimal. Although changes in the distribution of pneumo-
coccal serotypes have been observed among notified cases
of IPD since PCV introduction, the overall number of IPD
notifications remains unchanged [12–14]. Our study sug-
gests that cost considerations, as well as lack of knowledge
about pneumococcal disease and PCV among parents, re-
duces the value of vaccination, whatever the perceived
benefits. Parents of PCV-unvaccinated children are less
likely to have received a recommendation for vaccination.
Changes to reduce costs of PCV to families, targeted pub-
lic health messages to parents and healthcare profes-
sionals, and interventions to improve the perception of
the value of PCV vaccination have the potential to in-
crease PCV uptake in this community in Singapore.
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